ArriVent BioPharma, Inc. Common StockAVBPNASDAQ
LOADING
|||
Net Income Growth Under Pressure
Trending lower, above historical average.
Left:
||||
Year-over-year net income growth rate
Latest
-11.40%
↑ 48% above average
Average (14q)
-22.06%
Historical baseline
Range
High:51.23%
Low:-212.06%
Volatility
-1193.5%
Relatively stable
| Period | Value |
|---|---|
| Q3 2025 | -11.40% |
| Q2 2025 | 51.23% |
| Q1 2025 | -212.06% |
| Q4 2024 | -0.34% |
| Q3 2024 | 5.99% |
| Q2 2024 | -25.59% |
| Q1 2024 | 17.82% |
| Q4 2023 | -47.16% |
| Q3 2023 | 33.23% |
| Q2 2023 | -77.19% |
| Q1 2023 | -16.57% |
| Q4 2022 | 11.27% |
| Q3 2022 | -60.15% |
| Q2 2022 | 0.00% |
| Q1 2022 | 0.00% |